Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.

Bozdag M, Ferraroni M, Ward C, Carta F, Bua S, Angeli A, Langdon SP, Kunkler IH, Al-Tamimi AS, Supuran CT.

Eur J Med Chem. 2019 Aug 7;182:111600. doi: 10.1016/j.ejmech.2019.111600. [Epub ahead of print]

PMID:
31419777
2.

Development and characterisation of acquired radioresistant breast cancer cell lines.

Gray M, Turnbull AK, Ward C, Meehan J, Martínez-Pérez C, Bonello M, Pang LY, Langdon SP, Kunkler IH, Murray A, Argyle D.

Radiat Oncol. 2019 Apr 15;14(1):64. doi: 10.1186/s13014-019-1268-2.

3.

Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment.

Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Murray A, Argyle D.

Curr Top Microbiol Immunol. 2019 Mar 12. doi: 10.1007/82_2019_159. [Epub ahead of print]

PMID:
30859401
4.

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer.

Jarman EJ, Ward C, Turnbull AK, Martinez-Perez C, Meehan J, Xintaropoulou C, Sims AH, Langdon SP.

Breast Cancer Res. 2019 Jan 22;21(1):10. doi: 10.1186/s13058-019-1097-0.

5.

Biocompatibility of common implantable sensor materials in a tumor xenograft model.

Gray ME, Meehan J, Blair EO, Ward C, Langdon SP, Morrison LR, Marland JRK, Tsiamis A, Kunkler IH, Murray A, Argyle D.

J Biomed Mater Res B Appl Biomater. 2019 Jul;107(5):1620-1633. doi: 10.1002/jbm.b.34254. Epub 2018 Oct 27.

6.

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.

Xintaropoulou C, Ward C, Wise A, Queckborner S, Turnbull A, Michie CO, Williams ARW, Rye T, Gourley C, Langdon SP.

BMC Cancer. 2018 Jun 5;18(1):636. doi: 10.1186/s12885-018-4521-4.

7.

Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness.

Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ.

Metabolites. 2018 Feb 10;8(1). pii: E13. doi: 10.3390/metabo8010013. Review.

8.

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.

Kankia IH, Khalil HS, Langdon SP, Moult PR, Bown JL, Deeni YY.

Oxid Med Cell Longev. 2017;2017:1864578. doi: 10.1155/2017/1864578. Epub 2017 Dec 19.

9.

Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells.

Meehan J, Ward C, Turnbull A, Bukowski-Wills J, Finch AJ, Jarman EJ, Xintaropoulou C, Martinez-Perez C, Gray M, Pearson M, Mullen P, Supuran CT, Carta F, Harrison DJ, Kunkler IH, Langdon SP.

Oncotarget. 2017 Jun 27;8(26):42857-42875. doi: 10.18632/oncotarget.17143.

10.

Endocrine therapy in epithelial ovarian cancer.

Langdon SP, Gourley C, Gabra H, Stanley B.

Expert Rev Anticancer Ther. 2017 Feb;17(2):109-117. doi: 10.1080/14737140.2017.1272414. Epub 2016 Dec 24. Review.

11.

Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002.

Goltsov A, Tashkandi G, Langdon SP, Harrison DJ, Bown JL.

Eur J Pharm Sci. 2017 Jan 15;97:170-181. doi: 10.1016/j.ejps.2016.11.008. Epub 2016 Nov 8.

12.

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.

Khalil HS, Langdon SP, Goltsov A, Soininen T, Harrison DJ, Bown J, Deeni YY.

Oncotarget. 2016 Nov 15;7(46):75874-75901. doi: 10.18632/oncotarget.12425.

13.

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models.

Martínez-Pérez C, Ward C, Turnbull AK, Mullen P, Cook G, Meehan J, Jarman EJ, Thomson PI, Campbell CJ, McPhail D, Harrison DJ, Langdon SP.

Br J Cancer. 2016 Apr 12;114(8):905-16. doi: 10.1038/bjc.2016.6. Epub 2016 Mar 31.

14.

Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.

Koussounadis A, Langdon SP, Um I, Kay C, Francis KE, Harrison DJ, Smith VA.

BMC Cancer. 2016 Mar 10;16:205. doi: 10.1186/s12885-016-2212-6.

15.

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.

Khalil HS, Langdon SP, Kankia IH, Bown J, Deeni YY.

Oxid Med Cell Longev. 2016;2016:4148791. doi: 10.1155/2016/4148791. Epub 2015 Dec 7.

16.

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.

Huang R, Langdon SP, Tse M, Mullen P, Um IH, Faratian D, Harrison DJ.

Oncotarget. 2016 Jan 26;7(4):4695-711. doi: 10.18632/oncotarget.6618.

17.

Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers.

Briffa R, Um I, Faratian D, Zhou Y, Turnbull AK, Langdon SP, Harrison DJ.

PLoS One. 2015 Dec 17;10(12):e0144708. doi: 10.1371/journal.pone.0144708. eCollection 2015.

18.

Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis.

Verleyen W, Langdon SP, Faratian D, Harrison DJ, Smith VA.

Sci Rep. 2015 Oct 27;5:15563. doi: 10.1038/srep15563.

19.

Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrow.

Kunkler IH, Ward C, Langdon SP.

Breast. 2015 Nov;24 Suppl 2:S114-9. doi: 10.1016/j.breast.2015.07.026. Epub 2015 Oct 1. Review.

PMID:
26429399
20.

A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.

Xintaropoulou C, Ward C, Wise A, Marston H, Turnbull A, Langdon SP.

Oncotarget. 2015 Sep 22;6(28):25677-95. doi: 10.18632/oncotarget.4499.

Supplemental Content

Loading ...
Support Center